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To identify potential pharmacodynamic biomarkers to guide dose selection in clinical trials using anti-interferon-alpha (IFN-
α) monoclonal antibody (mAb) therapy for systemic lupus erythematosus (SLE), we used an Aﬀymetrix human genome array
platform and identiﬁed 110 IFN-α/β-inducible transcripts signiﬁcantly upregulated in whole blood (WB) of 41 SLE patients. The
overexpression of these genes was conﬁrmed prospectively in 54 additional SLE patients and allowed for the categorization of the
SLE patients into groups of high, moderate, and weak overexpressers of IFN-α/β-inducible genes. This approach could potentially
allow for an accurate assessment of drug target neutralization in early trials of anti-IFN-α mAb therapy for SLE. Furthermore, ex
vivo stimulation of healthy donor peripheral blood mononuclear cells with SLE patient serum and subsequent neutralization
with anti-IFN-α mAb or anti-IFN-α receptor mAb showed that anti-IFN-α mAb has comparable eﬀects of neutralizing the
overexpression of type I IFN-inducible genes as that of anti-IFNAR mAb. These results suggest that IFN-α, and not other members
of type I IFN family in SLE patients, is mainly responsible for the induction of type I IFN-inducible genes in WB of SLE patients.
Taken together, these data strengthen the view of IFN-α as a therapeutic target for SLE.
Copyright © 2009 Yihong Yao et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
The likelihood of gaining regulatory approval for new
medical therapies has decreased in recent years. On average,
a new drug entering phase I clinical testing is estimated
to have an 8% chance of reaching the market, a decrease
from the historical rate of 14% [1]. Major causes of clinical
trial failures include insuﬃcient drug activity (30%) and
unacceptable toxicity proﬁles (30%) [2]. The development
of robust pharmacodynamic (PD) markers is critical for
improvingthesuccessofdrugsinclinicaltrialsandwillguide
selection of an optimal drug dose to balance eﬃcacy and
toxicity [2]. PD markers are often proximal in a molecular
pathway to the drug target and are used to measure the eﬀect
of a drug regardless of therapeutic eﬀect. Another important
component that contributes to the success of new therapies
is the development of diagnostic biomarkers that may allow
better patient stratiﬁcation.
Biomarkers provide more information at earlier stages of
the clinical development process, thus helping to prioritize
drug discovery resources and allowing for better early deci-
sions on the fate of a development program. The US Food
and Drug Administration (FDA) recently published several
white papers that recognize the importance of biomarkers
in drug development and clinical trials [1, 3]. While the
FDA emphasized the need for biomarkers to demonstrate
target neutralization, it also expressed tremendous interest
in codeveloping diagnostic markers to target the correct
patient population, thereby improving the drug success
rate [3]. The FDA also has encouraged the adoption and
integration of genomic data in drug development and
regulatory assessment [4], initiating and spearheading the2 Human Genomics and Proteomics
MicroArray Quality Consortium (MAQC) project to assess
key factors contributing to the variability and reproducibility
of microarray data. The MAQC has shown that microarray
platforms are suitable tools to produce reliable, high-quality
datathatwillhelpdrugdevelopmentandregulatorydecision
making [4–6].
Systemic lupus erythematosus (SLE) is an autoimmune
disease that is characterized by severe immune system
defects and the production of autoantibodies that lead
to inﬂammation and tissue damage [7, 8]. The current
standard of care involves the use of corticosteroids and toxic
immunosuppressive agents that are widely acknowledged
to cause unacceptable adverse events with long-term use
[9]. Thus, novel therapies are needed that directly address
disease pathogenesis with less toxicity. Type I interferons
(IFNs) have been implicated in the development of SLE
for at least 25 years [7] ,a n de l e v a t e dl e v e l so fI F N - α are
detected in the serum of some SLE patients [7, 10, 11].
Previous results from microarray studies that investigated
gene expression proﬁles in the peripheral blood of SLE
patients have strengthened the idea that type I IFNs are
involved in disease pathogenesis [12–14]. Furthermore,
assayssuchasreal-timepolymerasechainreaction(RT-PCR)
havedemonstratedthatoverexpressionofIFN-α/β-inducible
genes correlated with increased disease severity and activity
in SLE patients [8].
We are currently exploring an anti-IFN-α monoclonal
antibody (mAb) as therapy for SLE and have used whole
genome array analysesto identify putative PD and diagnostic
biomarkers to aid in the development of the clinical trial.
Free IFN-α protein in the serum of SLE patients would be
the most reasonable choice for a PD marker for evaluating
an anti-IFN-α therapy in SLE. However, our internal studies
as well as others show that only a small fraction of SLE
patients have measurable IFN-α protein in the sera [8, 15–
17]. IFN-α-inducible genes, on the other hand, are directly
downstream of the drug target, are robustly overexpressed
in whole blood (WB) of the majority of SLE patients,
and can be quantitatively measured by either microarray
or TaqMan quantitative real-time reverse-transcriptase PCR-
(QRT-PCR-) based assays [12–14].
In this study, we have used the Aﬀymetrix human
genome plus U133v2.0 array platform to examine the
magnitude and prevalence of overexpression of IFN-α/β-
inducible genes in WB of SLE patients. Based on these
results, we selected a core group of IFN-α/β-inducible genes
and conﬁrmed the microarray results using TaqMan QRT-
PCR. Furthermore, we used ex vivo stimulation of healthy
donor peripheral blood mononuclear cells (PBMCs) with
SLE patient serum and subsequent neutralization with anti-
IFN-αmAboranti-IFN-αreceptor(IFNAR)mAbtoevaluate
the contribution of IFN-α to the induction of type I IFN-
inducible genes in WB of SLE patients.
2.MaterialsandMethods
2.1. Patients and Healthy Donor Controls. Two panels of
SLE patients were used in the study. The initial study panel
included 41 SLE patients. WB from these SLE patients was
procured from Asterand (Detroit, Mich, USA), Cureline
(South San Francisco, Calif, USA), and SeraCare (West
Bridgewater, Mass, USA). All SLE patients had a history of
at least 4 of 11 positive American College of Rheumatology
(ACR) classiﬁcation criteria for the diagnosis of SLE [18]
and active disease manifestations at the time of sample
collection. Thirty-nine (95%) were women, (mean ± SD
age of 40 ± 15 years). Thirty-two of 33 (97%) patients
who were tested for the presence of anti-nuclear antibodies
(ANA) came out positive. Thirty-one of 41 (76%) SLE
patients were currently receiving oral prednisone in doses
ranging from 1 to 30mg/day, with 2 SLE patients also
receiving pulse intravenous steroids. More than half (24/41)
of SLE patients were receiving at least 1 other potential
disease-modifying medication: hydroxychloroquine (n =
10), cyclophosphamide (n = 6), methotrexate (n = 4), aza-
thioprine (n = 2), cyclosporine (n = 1), or mycophenolate
mofetil (n = 1).
The prospective study panel included an independent set
ofSLEpatientsamplesthatwasusedtodemonstrateasimilar
distribution of patients with an overexpression of IFN-α/β-
induciblegenes.Allpatientsavailablefromaphase1aclinical
trial (MI-CP126) of patients were used for the purpose. This
panel included WB from 54 SLE patients from MI-CP126
investigating anti-IFN-α mAb therapy in mild-to-moderate
SLE. Patients (age ≥18 years) who met at least 4 of the 11
ACR criteria for SLE were enrolled in the trial. Stable SLE
background treatments with acetaminophen, nonsteroidal
anti-inﬂammatory drugs, antimalarials, and prednisone ≤
20mg/day or equivalent were allowed.Patients who were
receiving cyclophosphamide, azathioprine, methotrexate,
mycophenolate mofetil, cyclosporine, >20mg/day pred-
nisone (or equivalent), immunoglobulins, blood products,
investigational drugs, or antiviral therapies were excluded,
as well as patients with active or chronic infection, recent
vaccination with live attenuated viruses, recent herpes zoster,
history of severe herpes infection, active central nervous
system lupus, clinically signiﬁcant cardiac, cerebrovascular,
liver, or renal disease, or history of cancer.Most patients were
middle-aged Caucasian females with mild to moderately
active SLE with cutaneous involvement. The study was
conducted according to the Declaration of Helsinki, and
the study protocol was approved by the institutional review
boardat eachsite. Allpatients gavewritteninformed consent
before study-related procedures were performed.
The control group consisted of WB from 24 healthy
normal donors (age from 23 to 56; female: male ratio is
approximately 5:1) enrolled internally (MedImmune, LLC.).
All the blood donors gave written informed consent for the
blood to be taken and used in this study. The majority of
the donors were Caucasians. Table 1 provides demographic
information for the 3 groups described above.
A l lW Bf r o mS L Ep a t i e n t sa n dc o n t r o l sw e r ec o l l e c t e di n
PAXgene RNA tubes (PreAnalytiX GmbH) according to the
manufacturer’s instructions.
2.2. Total RNA Extraction and Microarray Processing.
Aﬀymetrix Human Genome U133 Plus 2.0 GeneChip arrays
were used in this study. Total RNA was extracted from WBHuman Genomics and Proteomics 3
Table 1: Patient demographic information.
Normal donors Initial panel Validation panel
Total N 24 41 54
Mean Age (SD) 33.7 (6.1) 40.0 (14.6) 44.9 (10.1)
Range 23–56 18–78 23–80
Gender (%Female) 77% 95% 96%
samples collected in PAXgene RNA tubes using the Qiagen
PAXgene Blood RNA kit (Valencia, Calif, USA). RNA purity
and concentration were determined spectrophotometri-
cally (260/280 > 1.9). The generation, fragmentation, and
hybridization of biotin-labeled ampliﬁed complementary
RNA (cRNA) were conducted as outlined in the Aﬀymetrix
GeneChip manual (Santa Clara, Calif, USA). The hybridiza-
tions were performed overnight and the washing/staining
of arrays and scanning were carried out consistent with
the standard Aﬀymetrix protocol. Data capture and initial
array quality assessment were performed with the GeneChip
Operating Software.
2.3. Ex Vivo Stimulation of WB from Healthy Donors with
Type I IFN Family Members. Ex vivo stimulation of WB was
conductedonbloodcollectedfrom3healthydonorsenrolled
internally (MedImmune, LLC.). Blood samples (6mL) were
exposed for treatments of vehicle (1× PBS), a panel of IFN-
α subtypes (IFN-α2a, -4b, -5, -6, -7, -8, -10, -14, -16, -17),
and IFN-β at concentration of 3 × EC50. All the cytokines
werepurchasedfromPBLBiomedical(Piscataway,NJ,USA).
Following dosing, the blood was incubated at 37◦C, 5% CO2
for 4 hours and transferred to a PAXgene RNA tube and
inverted 8 to 10 times. The PAXgene tubes were incubated
at room temperature for 2 hours and then frozen until
processed.
2.4. Microarray Data Analysis. ArrayAssist Lite software
(Stratagene,LaJolla,Calif,USA)wasusedtocalculateprobe-
level summaries (GC-RMA) from the array cell intensity
ﬁles (CEL). Signiﬁcance analysis of microarrays (SAMs)
with control of the false discovery rate was used to select
diﬀerentially regulated genes in SLE versus healthy controls
using R packages (R Development Core Team, University
of Auckland, New Zealand). Transcripts with a fold change
≥ 2a n dq value < 0.05 were considered to be diﬀerentially
regulated. Principal components analyses (PCAs) and hier-
archical clustering analyses were performed using SpotFire
(http://www.spotﬁre.com/)a n dRp a c k a g e s .
2.5. Pathway Analysis—GeneGo. Pathway and network anal-
ysis of gene expression data was conducted with the Meta-
CoreintegratedsoftwaresuitefromGeneGo,Inc.(St.Joseph,
Mich, USA) using the genes determined to be signiﬁcantly
regulated. The signiﬁcance of regulation, given a particular
pathwayornetwork,isapproximatedusingahypergeometric
distribution in which the P value represents the probability
of a particular gene set mapping arising by chance, given the
( 1 )n u m b e ro fg e n e si nt h es e to fa l lg e n e so np a t h w a ym a p s ,
(2) genes on a particular pathway map, and (3) genes in the
experiment.
2.6. TaqMan Low Density Array. The TaqMan Low Density
Array (TLDA; Applied Biosystems, Foster City, Calif, USA)
wasusedtodeterminethefold-changediﬀerentialforapanel
of 18 genes between WB of 27 SLE patients and pooled
RNA from 24 healthy controls. Genes printed on the array
included: 9 type I IFN-α s u b t y p e s( 1 ,2 ,5 ,6 ,7 ,8 ,1 4 ,1 7 ,
21),3additionaltypeIIFNs(IFN-β,-κ,-ω),IFN-γ,IFNαR1,
IFNαR2, IFNγR1, IFNγR2, and TNF-α. Double-stranded
cDNA for each patient sample was preampliﬁed using the
TaqMan PreAmp Master Mix kit (Applied Biosystems).
Standard procedures for loading the array were followed
and the array was run on a 7900HT Fast Real-Time PCR
System (Applied Biosystems). Data analysis of the resulting
Ct values was conducted with SDSv2.2.2 software (Applied
Biosystems).
2.7. Fluidigm BioMark System. Am i x t u r eo f4 4T a q M a n
Gene Expression Assays, including 4 reference control genes
(Applied Biosystems), was prepared using the TaqMan
PreAmp Master Mix Kit (Applied Biosystems). A total of 70
samples (35 from the 41 SLE patients in the original study
and 35 from the 54 SLE patients in the prospective study)
were run in triplicate (using 3 diﬀerent BioMark Real-Time
PCR Systems) against a set of 48 TaqMan Gene Expression
Assays in BioMark 48.48 dynamic array chips (Fluidigm
Corp., South San Francisco, Calif, USA). Dynamic arrays
were loaded using a NanoFlex 4-IFC Controller (Fluidigm
Corp.) and real-time reactions were performed using a
BioMark Real-Time PCR System (Fluidigm Corp.). Results
were analyzed using BioMark Real-Time PCR Analysis
software. Cts above 20 were excluded from the calculation.
Delta-delta Cts (ΔΔCt) were calculated using the mean of
4 reference genes (GAPDH, TFRC, β2M, and 18S) and a
calibrator sample.
2.8. Ex Vivo Stimulation of PBMCs from Healthy Donors with
Sera from SLE Patients. SLE serum samples were selected
based on levels of type I IFN activity as determined by
a reporter gene assay as previously described with some
modiﬁcations [19]. Brieﬂy, HEK293H cells were stably
transfected with a luciferase construct (Gaussia princeps)
under the control of the IFN-stimulated response element
(ISRE). Transfected cells were incubated with 50% patient
sera, and luciferase activity was detected in the culture
supernatants 24 hours later. Samples generating a signal
greaterthan1.5timesofthenegativecontrol(normalhuman
serum)wereconsideredpositive.TodeterminewhetherIFN-
α was responsible for the positive response, cells were treated
with an anti-IFN-α mAb (human IgG1; MedImmune, LLC.)
and percent neutralization was calculated. Serum samples
were selected for ex vivo stimulation of healthy donor PBMC
based on their level of IFN-α activity.
PBMCs were harvested from WB of a healthy volunteer
using Ficoll-Pacque gradient centrifugation according to
manufacturer’s instructions (GE Life Sciences, Uppsala,4 Human Genomics and Proteomics
Sweden) and were resuspended in RPMI 1640 media with
GlutaMAX containing 10% fetal bovine serum (Invitrogen,
Carlsbad, Calif, USA). To measure the eﬀects of SLE serum
on the healthy donor cells, PBMCs were cultured at a density
of5×106 cells/mLin250μL/wellofa24-wellplatecontaining
25% SLE patient serum, in the presence or absence of the
following neutralizing antibodies: anti-human-IFN-α (0.1,
1, and 10μg/mL; human IgG1; MedImmune, LLC.), anti-
human IFN-γ (10μg/mL; mouse IgG1, clone MMHG-1;
PBL), anti-human-IFNAR1 (10μg/mL; human IgG1; Med-
Immune, LLC.), and anti-HIVgp120 as a negative control
(10μg / m L ;h u m a nI g G 1 ,M e d I m m u n e ,L L C . ) .F o l l o w i n g
4-hour incubation at 37◦C ,c e l l sw e r et r e a t e dw i t hT r i z o l
LS (Invitrogen) and stored at −70◦Cf o rs u b s e q u e n tR N A
isolation.
In a pilot study, we observed that the same SLE serum
sample elicited very comparable responses in inducing the
overexpression of IFN-α/β-inducible genes in PBMCs from
3 healthy donors (data not shown). This allowed us to limit
the assay to 1 healthy donor PBMCs so that more SLE
serum samples could be included in the study. Therefore, we
selected 6 SLE serum samples based on their IFN-a bioassay
results described above and used these samples to stimulate
PBMCs from one healthy donor. This provided a total of
42 microarray experiments (i.e., 6 sera samples from SLE
patients × 7 conditions).
3. Results
3.1. Ex Vivo Stimulation of Healthy Donor WB with IFN-
α Subtypes and IFN-β. To determine the prevalence and
magnitude of the overexpression of IFN-α/β-inducible genes
inWBofSLEpatients,weﬁrstcarriedoutexvivostimulation
of healthy donor WB with diﬀerent members of the type
I IFN family (see Section 2) to identify IFN-α/β-inducible
genes. Three samples were then subjected to transcript
proﬁling using Aﬀymetrix Human Genome U133 Plus 2.0
GeneChip array. Three biological replicates of healthy donor
WB were stimulated with each of the 10 IFN-α subtypes or
IFN-β (see Section 2). For each trio of cytokine treatments, a
pairedStudent’st-testandaveragefoldchangewascalculated
between the three cytokine treatment replicates and the
three untreated healthy donor WB samples. Only those
probes that exhibited at least a 2-fold change and P<. 05
across all cytokine treatments were retained (the small sizes
in each comparison restricted the use of multiple testing
adjustment). We observed that 807 and 562 transcripts were
uniformlyupregulatedanddownregulated,respectively,after
stimulation of WB of 3 healthy donors with each of 10 IFN-α
subtypes or IFN-β for 4 hours.
3.2. Overexpression of IFN-α/β-Inducible Genes is Robust
and Prevalent in WB of SLE Patients. To identify candidate
PD markers for anti-IFN-α mAb clinical trials in SLE, we
utilized the Aﬀymetrix array platform to proﬁle WB from
41 SLE patients in the initial study and 24 healthy donors.
We observed that 239 and 88 transcripts were upregulated
and downregulated, respectively, in WB of SLE patients
compared with healthy controls. Of the 239 transcripts
upregulated in WB of SLE patients, 110 were IFN-α/β-
inducible (as deﬁned by ex vivo stimulation of WB with
type I IFN family members). Table 2 lists the 50 most
upregulated transcripts in WB of SLE patients from the
initial study; 74% of them are IFN-α/β-inducible. Table 2
also lists the prevalence of the overexpression of these genes
in WB of SLE patients. These genes are overexpressed by at
least 2 folds in 49% to 80% of the patients proﬁled. The
robust and prevalent overexpression of a large number of
IFN-α/β-inducible genes in SLE patients suggests that these
genes might be suitable PD markers for clinical trials that
investigate an anti-IFN-α mAb therapy for SLE.
Figure 1 shows a heat map of the expression of the
110 upregulated IFN-α/β-inducible transcripts in WB of
41 SLE patients in the initial study compared to healthy
controls. A total of 30/41 of the SLE patients proﬁled
showed signiﬁcant overexpression of the IFN-α/β-inducible
gene signature. To quantify the magnitude of overexpression
of IFN-α/β-inducible genes in WB of SLE patients, we
developed an algorithm that takes advantage of the whole
genome array approach. Brieﬂy, we selected the 25 most
highly overexpressed IFN-α/β-inducible genes in individual
SLE patients based on the 807 IFN-α/β-inducible transcripts
generated from the ex vivo stimulation of healthy donor
WB study, and used the median fold change of these 25
genes to construct an IFN-α/β-inducible gene signature
score for each SLE patient. Figure 2 shows the distribution
of the IFN-α/β-inducible gene signature scores of the 41
SLE patients in the initial study. We classiﬁed the SLE
patients into 3 groups based on their IFN-α/β-inducible
gene signature score: high IFN-α/β-inducible gene signature
(score > 10); moderate IFN-α/β-inducible gene signature
(score 4–10); and weak IFN-α/β-inducible gene signature
(score < 4). The classiﬁcation of SLE patients based on IFN-
α/β-inducible gene signature score is mainly for the purpose
of evaluating PD in the early phases of clinical trials of anti-
IFN-α mAb therapy in SLE. The SLE patients with a weak
or nondetectable IFN-α/β-inducible gene signature score are
unlikelytoprovideaccurateassessmentofthepharmacologic
eﬀect of anti-IFN-α mAb in these patients. Figure 3(a) shows
the PCA plot of the 41 SLE patients in the initial study
using the 110 overexpressed IFN-α/β-inducible transcripts.
We observed a clear diﬀerence between SLE patients that
had distinct overexpression of the IFN-α/β-inducible gene
signature from healthy donors and SLE patients that had a
weak or nondetectable IFN-α/β-inducible gene signature in
WB.
To validate the observation that IFN-α/β-inducible genes
are overexpressed in WB of SLE patients, we procured
WB from 54 SLE patients enrolled in a prospective study.
Figure 3(b) shows the PCA plot from the 54 SLE patients
using the same 110 IFN-α/β-inducible transcripts identiﬁed.
We observed a very similar separation of SLE patients based
on the IFN-α/β-inducible gene signature as in Figure 3(a).
The distribution of the IFN-α/β-inducible gene signature
score in the prospective study was also similar to that
of the initial study (data not shown). The ability to use
the overexpressed IFN-α/β-inducible genes identiﬁed toHuman Genomics and Proteomics 5
Table 2: Fold changes (fc; log2 transformed) and q values (calculated using FDR) for the top 50 most upregulated transcripts in WB of SLE
patients. Data were generated from 41 SLE patients in the initial study and 24 healthy controls using SAM and FDR in R (see Section 2).
IFN-α/β-inducible genes are bolded. Prevalence is deﬁned as the percentage of patients exhibiting greater than 2-fold overexpression for a
transcript compared with the baseline that is deﬁned by the average of 24 healthy controls. FDR = false discovery rate; IFN = interferon; SAM
= signiﬁcance analysis of microarrays; SLE = systemic lupus erythematosus; WB = whole blood.
Probe ID Gene title Gene symbol p value log2 fc q value (FDR)
Probe
prevalence
(% fc ≥ 2)
202411 at Interferon,alpha-inducible protein 27 IFI27 2.69E-08 4.40 0.00001 70.73
219519 s at Sialic acid binding1g-likelectin 1,sialoadhesin SIGLEC1 1.79E-08 3.40 0.00001 63.41
214059 at Interferon-inducedprotein 44 IFI44 2.94E-08 3.33 0.00001 70.73
204415 at Interferon,alpha-inducible protein 6 IFI6 9.71E-12 3.13 0.00000 80.49
213797 at Radical S-adenosyl methioninedomain containing 2 RSAD2 1.11E-06 3.10 0.00013 68.29
242625 at Radical S-adenosyl methioninedomain containing 2 RSAD2 9.45E-08 3.04 0.00003 65.85
204439 at Interferon-inducedprotein 44-like IFI44L 5.79E-07 2.94 0.00008 68.29
219211 at Ubiquitinspeciﬁcpeptidase 18 USP18 2.09E-07 2.66 0.00005 63.41
214453 s at Interferon-inducedprotein 44 IFI44 1.33E-06 2.55 0.00014 70.73
207329 at Matrix metallopeptidase 8 (neutrophil collagenase) MMP8 8.90E-05 2.54 0.00219 60.98
202145 at Lymphocyte antigen6 complex, locus E LY6E 1.80E-08 2.42 0.00001 60.98
212768 s at Olfactomedin 4 OLFM4 0.000652117 2.28 0.00847 60.98
202869 at 2 ,5 -oligoadenylate synthetase1, 40/46kDa OAS1 4.70E-08 2.25 0.00002 68.29
231688 at Transcribed locus — 0.000279919 2.23 0.00474 63.41
44673 at Sialic acid binding1g-likelectin 1,sialoadhesin SIGLEC1 9.90E-08 2.23 0.00003 56.10
208470 s at Haptoglobin /// haptoglobin-related protein HP /// HPR 5.60E-07 2.22 0.00008 80.49
1555643 s at Leukocyte immunoglobulin-like receptor, subfamily A
(with TM domain), member 5
LILRAE 2.32E-09 2.21 0.00000 75.61
222154 s at ViralDNApolymerase-transactivatedprotein6 LOC26010 1.31E-06 2.21 0.00014 63.41
206697 s at Haptoglobin HP 5.16E-07 2.20 0.00008 73.17
242234 at XIAPassociatedfactor-1 XAF1 3.06E-08 2.17 0.00001 63.41
241869 at Apolipoprotein L, 6 APOL6 2.86E-05 2.16 0.00102 78.05
235643 at Sterile alpha motifdomain containing 9-like SAMD9L 1.U8E-08 2.14 0.00001 82.93
206871 at Elastase 2, neutrophil ELA2 0.00014434 2.14 0.00305 58.54
215838 at Leukocyte immunoglobulin-like receptor, subfamily A
(with TM domain), member 5
LILRA5 3.10E-07 2.13 0.00006 73.17
239979 at — — 2.59E-07 2.11 0.00005 63.41
218400 at 2 -5 -oligoadenylate synthetase3, 100kDa OAS3 1.27E-06 2.11 0.00014 65.85
203153 at Interferon-inducedprotein with tetratricopeptide
repeats 1
IFIT1 1.66E-05 2.11 0.00072 65.85
205552 s at 2 ,5 -oligoadenylate synthetase1, 40/46kDa OAS1 1.11E-08 2.10 0.00001 63.41
222816 s at Zinc ﬁnger, CCHC domain containing 2 ZCCHC2 1.56E-06 2.05 0.00015 78.05
205483 s at I5015ubiquitin-likemodiﬁer ISG15 2.07E-07 2.05 0.00004 63.41
227609 at Epithelial stromalinteraction 1 (breast) EPSTII 3.85E-07 2.05 0.00006 65.85
203757 s at Carcinoembryonic antigen-related cell adhesion
molecule 6 (non-speciﬁc cross reacting antigen)
CEACAM6 8.59E-05 2.01 0.00215 48.78
237340 at Solute carrier family 26, member 8 SLC26A8 1.25E-07 1.96 0.00003 60.98
205569 at Lysosomal-associatedmembraneprotein3 LAMPS 3.51E-07 1.95 0.00006 60.98
211657 at Carcinoembryonic antigen-related cell adhesion
molecule 6 (non-speciﬁc cross reacting antigen)
CEACAM6 0.000687104 1.94 0.00878 60.98
226702 at Hypothetical proteinLOC129607 LOCI 29607 1.08E-05 1.94 0.00055 65.85
200986 at Serpinpeptidaseinhibitor,clade G (C1inhibitor),
member 1, (angioedema, hereditary)
SERPING1 1.52E-05 1.92 0.00068 65.85
219863 at Hect domainandRLD 5 HERCS 2.03E-06 1.92 0.00018 65.85
204747 at Interferon-inducedprotein with tetratricopeptide
repeats 3
IFIT3 8.97E-08 1.92 0.00003 65.856 Human Genomics and Proteomics
Table 2: Continued.
Probe ID Gene title Gene symbol p value log2 fc q value (FDR)
Probe
prevalence
(% fc ≥ 2)
219684 at Receptor (chemosensory) transporterprotein 4 RTP4 8.65E-08 1.91 0.00003 60.98
224225 s at ets variant gene 7 (TEL2 oncogene) ETV7 3.36E-06 1.88 0.00026 53.66
206133 at XIAPassociatedfactor-1 XAF1 2.58E-08 1.85 0.00001 63.41
235276 at Epithelial stromalinteraction 1 (breast) EPSTII 3.97E-07 1.85 0.00007 63.41
241916 at Transcribedlocus — 1.61E-07 1.85 0.00004 73.17
207802 at Cysteine-rich secretory protein 3 CRISP3 0.000877786 1.84 0.01042 60.98
238439 at Ankyrinrepeat domain 22 ANKRD22 5.94E-07 1.84 0.00008 65.85
228439 at Basicleucine zipper transcriptionfactor, ATF-like2 BATF2 1.41E-06 1.83 0.00014 60.98
217502 at Interferon-inducedprotein with tetratricopeptide
repeats 2
IFIT2 3.82E-07 1.83 0.00006 68.29
202086 at Myxovirus(inﬂuenza virus)resistance1,
interferon-inducibleprotein p78 (mouse)
MX1 2.68E-06 1.83 0.00022 65.85
203595 s at Interferon-inducedprotein with tetratricopeptide
repeats 5
IFITS 1.71E-10 1.82 0.00000 68.29
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Figure 1: Representative heat map visualizing the overexpression of IFN-α/β-inducible gene signature, granulocyte signature, and
underexpression of T-cell and B-cell signature in WB from 41 SLE patients ( ) compared with WB from 24 healthy donors ( ). IFN =
interferon; SLE = systemic lupus erythematosus.
segregate SLE patients into 2 distinct groups—patients with
or without IFN-α/β-inducible gene signature—validated the
accurate identiﬁcation of overexpression in the IFN-α/β-
inducible gene signature in WB of SLE patients.
We also observed the overexpression of a gene signature
that is indicative of granulocyte activation in WB of SLE
patients. This granulocyte signature was present in about
50% of the SLE patients proﬁled and included but was not
limited to the following genes: AZU, DEFA1, DEFA4, ELA2,
MMP8, MMP9, RNAS2, MPO, CAMP, FCAR, and CYBB
(Figure 1). The downregulation of T and B cell gene signa-
tures was also observed in WB of SLE patients (Figure 1),
and is consistent with the observation of lymphopenia in the
peripheral blood of SLE patients that has been previously
reported in the literature [13, 20]. Table 3 lists the 50 most
downregulated transcripts observed in WB of SLE patients.
To further conﬁrm our observation of overexpression
of the IFN-α/β-inducible and granulocyte gene signatures,
and to identify other signaling pathways that may be altered
in SLE, we carried out a pathway and network analysis
with GeneGo software (see Section 2). Overall, this pathway
analysis conﬁrmed the activation of the type I IFN signaling
pathway, along with the activation of granulocytes and
the downregulation of T-cell signaling pathways in SLE.
The interleukin (IL)-10 signaling pathway was among other
notable pathways found to be activated or, otherwise, altered
in the SLE patients who were proﬁled. This is likely due to
the abnormal apoptosis of T-cell subsets observed in SLE
patients [21, 22].
3.3. Conﬁrmation of the Overexpression of IFN-α/β-Inducible
Genes Identiﬁed by Microarrays Using TaqMan QRT-PCR
Assays. To conﬁrm the overexpression of IFN-α/β-inducible
genes in WB of SLE patients, which was observed in the
microarray analyses, we used a BioMark 48.48 dynamic array
to perform the high-throughput TaqMan QRT-PCR on theHuman Genomics and Proteomics 7
Table 3: Fold changes (fc; log2 transformed) and q values (calculated using FDR) for the top 50 most downregulated transcripts in WB of
SLE patients. Data were generated from 41 SLE patients in the initial study and 24 healthy controls using SAM and FDR in R (see Section 2).
FDR = false discovery rate; SLE = systemic lupus erythematosus; SAM = signiﬁcance analysis of microarrays; WB = whole blood.
Probe ID Gene title Gene symbol log2 fc q value (FDR)
1552713 a at Solute carrier family 4, anion exchanger, member 1 SLC4A1 −1.81 0.00053
1552348 at Protease, serine, 33 PRSS33 −1.55 0.00172
214470 at Killer cell lectin-like receptor subfamily B, member 1 KLRB1 −1.53 0.00002
236307 at Transcribed locus — −1.51 0.00039
211734 s at Fc fragment of IgE, high aﬃnity I, receptor for; alpha polypeptide FCERIA −1.50 0.00325
209570 s at DNA segment on chromosome 4 (unique) 234 expressed sequence D4S234E −1.48 0.00000
227198 at AF4/FMR2 family, member 3 AFF3 −1.45 0.00051
217143 s at T cell receptor alpha locus /// T cell receptor delta locus TRA@ /// TRD@ −1.40 0.00001
232286 at CDNA FLJ12187 ﬁs, clone MAMMA1000831 — −1.40 0.00005
209815 at Patched homolog 1 (Drosophila) PTCH1 −1.36 0.00006
207840 at CD160 molecule CD160 −1.36 0.00150
209993 at ATP-binding cassette, sub-family B (MDR/TAP), member 1 ABCB1 −1.33 0.00004
203562 at Fasciculation and elongation protein zeta 1 (zygin I) FEZ1 −1.33 0.00047
239673 at Transcribed locus — −1.31 0.00014
231798 at Noggin NOG −1.31 0.00257
213674 x at Immunoglobulin heavy constant delta IGHD −1.31 0.01987
1553177 at SH2 domain containing 1B SH2D1 B −1.26 0.00245
236796 at BTB and CNC homology 1, basic leudne zipper transcription
factor 2
BACH2 −1.26 0.00010
229513 at Spermatid perinudear RNA binding protein STRBP −1.25 0.00024
241881 at — — −1.24 0.03229
235400 at Fc receptor-like A FCRLA −1.23 0.00071
221748 s at Tensin 1 TNS1 −1.22 0.01582
228599 at Membrane-spanning 4-domains, subfamily A, member 1 MS4A1 −1.20 0.00504
239278 at CDNA clone IMAGE:5301129 — −1.19 0.00003
243810 at Transcribed locus — −1.18 0.00041
218864 at Tensin 1 TNS1 −1.18 0.01461
243054 at Transcribed locus — −1.17 0.00192
232478 at CDNA clone IMAGE: 4815026 — −1.17 0.00008
235401 s at Fc receptor-like A FCRLA −1.17 0.00103
212827 at Immunoglobulin heavy constant mu IGHM −1.17 0.00422
240690 at — — −1.17 0.00039
211532 x at Killer cell immunoglobulin-like receptor, two domains, short
cytoplasmic tail, 2
KIR2DS2 /// KIR2 −1.16 0.03318
202458 at Protease, serine, 23 PRSS23 −1.16 0.00386
216191 s at T cell receptor alpha locus /// T cell receptor delta locus TRA@ /// TRD@ −1.15 0.01010
243798 at Transcribed locus — −1.15 0.00054
244878 at Transcribed locus — −1.14 0.00008
233921 s at CDNA FLJ12016 ﬁs, clone HEMBB1001707 — −1.14 0.00003
219630 at PDZK1 interacting protein 1 PDZKIIP1 −1.14 0.01175
1563217 at CDNA clone IMAGE: 5299732 — −1.13 0.00040
203661 s at Tropomodulin 1 TMOD1 −1.13 0.01237
212599 at Autism susceptibility candidate 2 AUTS2 −1.13 0.00210
210746 s at Erythrocyte membrane protein band 4.2 EPB42 −1.13 0.01138
213183 s at Cydin-dependent kinase inhibitor IC (p57, Kip2) CDKN1 C −1.13 0.00091
1556451 at MRNA; cDNA DKFZp667B1520 (from clone DKFZp667B1520) — −1.12 0.00106
242509 at — — −1.12 0.000268 Human Genomics and Proteomics
Table 3: Continued.
Probe ID Gene title Gene symbol log2 fc q value (FDR)
204793 at G protein-coupled receptor associated sorting protein 1 GPRASPI −1.12 0.00044
232686 at Sialic acid binding Ig-like lectin, pseudogene 3 SIGLECP3 −1.12 0.00006
209994 s at ATP-binding cassette, sub-family B (MDR/TAP), member 1 ABCB1 /// ABCB4 −1.12 0.00001
230245 s at Hypothetical protein LOC283663 LOC283663 −1.11 0.01218
209569 x at DNA segment on chromosome 4 (unique) 234 expressed sequence D4S234E −1.11 0.00008
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Figure 2: Magnitude of overexpression of IFN-α/β-inducible gene
signature in WB of 41 SLE patients in the initial study as measured
by the median fold change of the 25 most overexpressed IFN-
α/β-inducible genes (IFN-α/β-inducible gene signature score) in
individual SLE patients. The horizontal bars represent the median
values. Patients whose IFN-α/β-inducible gene signature score
was >10 were considered to have high IFN-α/β-inducible gene
signatures; those with scores between 4 and 10 were considered
to have moderate IFN-α/β-inducible gene signatures, whereas
those with scores < 4 were considered to have weak IFN-α/β-
inducible gene signatures. IFN = interferon; SLE = systemic lupus
erythematosus.
top 40 most overexpressed IFN-α/β-inducible genes in WB
of SLE patients. The overexpression of all these genes was
conﬁrmed by TaqMan QRT-PCR assays in WB of 35 of
the 41 SLE patients randomly selected from the original
study, and also 35 of the 54 SLE patients selected from
the prospective study. The majority of the data showed a
strong correlation between microarray and TaqMan assays.
The overexpression of 15 of the 40 IFN-α/β-inducible genes
using TaqMan assays is shown in Figure 4(a). These genes
were upregulated by an average of 8- to 92-fold, and all were
signiﬁcantly overexpressed (P<. 05).
3.4. mRNAs of Type I IFN Family Members are Overexpressed
in SLE Patients Using TaqMan QRT-PCR Assays. Given that
we observed signiﬁcant overexpression of IFN-α/β-inducible
genes in WB of SLE patients, we wanted to characterize the
type I IFNs that may be responsible for this upregulation.
Since the type I IFN protein can only be measured in a small
fraction of SLE patients, we used the TLDA technology from
Applied Biosystems to measure the mRNA level of type I IFN
family members in WB of 27 SLE patients, and compared
that with pooled RNA from WB of 24 healthy donors.
We found that the overexpression of mRNAs of 9 IFN-α
subtypes in WB of SLE patients was signiﬁcant (P<. 01)
compared with healthy controls (Figure 5(a)). In addition,
the mRNAs of other type I IFN family members, such as
IFN-β and IFN-ω, were also signiﬁcantly overexpressed in
SLE (P<. 0 1 ) ,a sw e r et h et y p eII F Nr e c e p t o r sI F N A R 1
and IFNAR2 (Figure 5(b)). These observations suggest that
upregulation of mRNAs of type I IFN family members
may contribute to the overexpression of their respective
proteins, which may in turn underscore the overexpression
of IFN-α/β-inducible gene signature in WB of SLE patients.
Furthermore, we observed that TNF-α,I F N - γ, IFNGR1, and
IFNGR2 transcripts were also upregulated in WB of SLE
patients (Figure 5(c)). However, the relative magnitude of
overexpression of these transcripts was much less than those
of type I IFN family members, especially the IFN-α subtypes
(Figures 5(a) and 5(b)).
3.5. Identiﬁcation of a Panel of IFN-α/β-Inducible Genes that
are Neutralized by an Anti-IFN-α mAb. Among the 807 IFN-
α/β-inducible transcripts originally identiﬁed, we aimed to
eliminategenesthatwerelikelytobeupregulatedbymultiple
cytokines in SLE or poorly neutralized by anti-IFN-α mAb
in SLE (rendering them poor candidates as PD markers
in clinical trials investigating anti-IFN-α mAb therapy in
SLE). One of the approaches to address these issues was
to identify the IFN-α/β-inducible genes induced in healthy
donor PBMC ex vivo by SLE patient sera that were also
neutralized by anti-IFN-α mAb.
Overall, sera from 6 SLE patients were characterized
based on their level of IFN-α activity as measured in an ISRE
reporter gene assay, and were used to stimulate PBMC of
one healthy donor ex vivo. There was a positive correlation
between the IFN-α activity in serum of SLE patients and the
magnitude of IFN-α/β-inducible genes induced as measured
by the IFN-α/β-inducible gene signature score (data not
shown). A total of 436 of 807 IFN-α/β-inducible transcripts
were upregulated by more than 2 folds when challenged with
at least one SLE patient serum. Of these 436 transcripts, the
overexpressionof161wasinhibited ≥50%whentreatedwith
the highest dose of anti-IFN-α mAb (6 total samples), and
inhibition of ≥70% for any sample treated with the single
dose of anti-IFNAR1 mAb (6 total samples). The heat map
demonstrating the eﬀects of anti-IFN-α and -γ and anti-
IFNAR1 mAbs on the genes upregulated in healthy donor
PBMC by treatment with the serum of one SLE patient is
shown in Figure 6. The anti-IFN-α mAb treatment (lanes
4–6) demonstrated a strong neutralizing eﬀect on a largeHuman Genomics and Proteomics 9
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Figure 3: IFN-α/β-inducible genes in WB of SLE patients can be used to separate SLE patients with IFN-α/β-inducible gene signature from
healthy normal controls. (a) Three-dimensional PCA plot of WB from 41 SLE patients in the initial study using the 110 upregulated IFN-
α/β-inducible transcripts upregulated in WB of SLE patients compared with those from 24 healthy donors. (b) PCA plot of WB from 54
SLE patients in the prospective study using the same 110 upregulated IFN-α/β-inducible transcripts conﬁrmed the overexpression of IFN-
α/β-inducible gene signatures in SLE patients. (c) PCA plot of WB from 95 SLE samples in both discovery and prospective study using the
21 upregulated IFN-α/β-inducible gene panel in SLE patients compared with 24 healthy donors. Each point represents one sample (blue
points: healthy normal controls; red points: SLE patients). IFN = interferon; PCA = principal components analysis; SLE = systemic lupus
erythematosus.
number of genes stimulated with the serum of an SLE
patient. Furthermore, the neutralizing eﬀect of the anti-IFN-
αmAbwasdose-dependent,asevaluatedbythediﬀerencesin
the number of transcripts that were inhibited by treatment
with anti-IFN-α mAb ≥50% at each of the 3 dosage levels
(0.1,1,and10μg/mL)withineachofthe6SLEpatientserum
samples. For example, the mean ± SD normalized ratios of
the number of inhibited transcripts ≥50% between 0.1, 1,
and 10μg/mL treatments of anti-IFN-α mAb and 10μg/mL
treatment of anti-IFNAR mAb are 1.00, 1.96 ± 0.57, 2.28 ±
0.72, and 2.94 ± 1.04, respectively. This suggests that these
genes might be good candidates for PD markers for clinical10 Human Genomics and Proteomics
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Figure 4: TaqMan QRT-PCR conﬁrmed the overexpression of IFN-α/β-inducible genes in WB of SLE patients. (a) Relative fold changes of
15 IFN-α/β-inducible genes (out of the 40 assayed) in SLE patients were compared with healthy donors (P<. 05 for all). Averages of relative
mRNA levels of genes in the pooled RNA from 24 healthy donors were scaled to 1 based on TaqMan QRT-PCR assays. Horizontal bars
represent average fold change. (b) TaqMan QRT-PCR validation of overexpression of the 21-gene panel of IFN-α/β-inducible genes in WB
of SLE patients as determined by whole genome array. The relative overexpression of 21 IFN-α/β-inducible genes in 2 SLE patients is shown
via (left) microarray and (right) TaqMan assays. Correlation coeﬃcients (r) between TaqMan QRT-PCR and microarray were 0.986 and
0.989 for patient X and Y, respectively. IFN = interferon; QRT-PCR = quantitative real-time reverse transcriptase polymerase chain reaction;
SLE = systemic lupus erythematosus.
trialsevaluatinganti-IFN-αmAbtherapyinSLE.Thecontrol
mAb inhibited the overexpression of some genes upregulated
when challenged with SLE patient sera (including IFN-α/β-
inducible genes) (lane 2). However, the eﬀect of the anti-
IFN-α mAb was much broader, with a strong neutralizing
eﬀect observed in a large number of genes in which neither
the reference mAb nor anti-IFN-γ mAb had any signiﬁcant
eﬀect (lanes 2-3; lanes 4–6). When examining the mean
± SD percentage of genes inhibited ≥50% by each of the
antibody treatments, there is a much stronger eﬀect on gene
counts for the 10μg/mL treatments of anti-IFN-α mAb and
anti-IFNAR mAb (17 ± 8% and 22 ± 11% genes inhibited,
resp.), as compared to the treatments of anti-IFN-γ and the
control mAb (8 ± 5% and 6 ± 6% genes inhibited, resp.). ItHuman Genomics and Proteomics 11
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Figure 5: Relative expression of mRNAs and median fold changes
(horizontal bars) of (a) type I IFN-α subtypes, (b) other members
o ft h et y p eII F N sa n dI F N - α receptors, and (c) TNF-α,I F N - γ,
and IFN-γ receptors in WB of SLE patients compared with healthy
controls (P ≤ .05 for all). Averages of relative mRNA levels of these
cytokines and their receptors in WB from 24 healthy donors were
scaled to 1 based on TaqMan QRT-PCR assays. IFN = interferon;
QRT-PCR =quantitativereal-timereversetranscriptasepolymerase
chain reaction; SLE = systemic lupus erythematosus; TNF-α =
tumor necrosis factor.
shouldbenotedthattreatmentwithanti-IFNAR1mAb(lane
7) induced a greater neutralization than anti-IFN-α mAb,
suggesting the possible presence (although of minor eﬀect)
of other type I IFN family members in addition to IFN-α in
the serum of the SLE patient.
3.6.Selectionofa21-GenePanelofIFN-α/β-InducibleGenesas
PotentialPDandDiagnosticBiomarkerstoValidateinClinical
Trials. To select a small, robust panel of IFN-α/β-inducible
genes that could be developed into a high-throughput PD
marker assay to measure anti-IFN-α mAb eﬀect in SLE, we
narrowed the gene panel to 21 genes so that they could
be assayed by either TLDAs or Fluidigm BioMark 48.48
dynamic array chips. The process for the selection of 21 IFN-
α/β-inducible genes as candidate PD markers to measure
anti-IFN-α mAb therapy in SLE is outlined in Figure 7.
Brieﬂy, we started with 807 IFN-α/β-inducible transcripts
identiﬁed byex vivo stimulation of WB of 3 healthy donors
with 10 IFN-α subtypes and IFN-β. Then, we identiﬁed that
110 overexpressed transcripts (q<0.05; fold change ≥ 2)
in WB of 41 SLE patients in the initial study were IFN-α/β-
inducible using SAM and FDR.
To identify whether these genes could be neutralized by
an anti-IFN-α mAb in SLE, we stimulated 1 healthy donor
PBMC ex vivo with sera from 6 individual SLE patients. We
observed that 161 (of the 807 transcripts) IFN-α/β-inducible
transcripts were upregulated by ≥2 folds in the PBMC of
the healthy donor following stimulation with at least 1 SLE
patient serum in which the overexpression of these genes was
suppressed by ≥50% and ≥70% by an anti-IFN-α mAb and
an anti-IFN-αRm A b ,r e s p e c t i v e l y .
77 transcripts were common to this list of 161 transcripts
(identiﬁed in the neutralization experiments) and the pre-
viously determined list of 110 transcripts (identiﬁed to be
overexpressed in WB of 41 SLE patients). These transcripts
are both IFN-α/β-inducible and can be neutralized by an
anti-IFN-αmAb.Eachofthe77transcriptswasrankedbythe
average fold-change magnitude across all SLE patients and
the percentage of patients displaying a change ≥2f o l d s .T h e
21 most prevalently overexpressed IFN-α/β-inducible genes
(that represent unique genes using the NetAﬀx annotation
ﬁle for the Aﬀymetrix U133v2.0 plus array; ESTs were
excluded) from this ranking were selected as candidate PD
markers for anti-IFN-α therapy in SLE. Four genes: OAS2,
MX1, PLSCR1, and DNAPTP6 were chosen over a few other
candidate genes that showed slightly higher overexpression
in WB of SLE patients due to the strong indication from
the literature of their involvement in SLE, antiviral response,
or involvement in type I IFN signaling pathway [23–25].
A 21-gene panel was chosen so that the high-throughput
TaqMan assays can be carried out on the TDLA array.
Table 4 lists the 21 IFN-α/β-inducible genes in WB of 95 SLE
patients from both initial and prospective studies described
earlier. The consistency of the results in both microarray and
TaqMan assays and the strong correlation (r>0.98) between
microarray and TaqMan assays for 21 IFN-α/β-inducible
genes in the 2 example SLE patients (Figures 4(b)) provide
more evidence that these genes may be useful as PD and
diagnostic markers of anti-IFN-α treatment in SLE as they
are robustly measured using multiple assay platforms.
With these 21 genes, it was necessary to recalculate
the thresholds of IFN-α/β-inducible gene signature score
in WB of SLE patients that were previously identiﬁed for
partitioning SLE patients into high, moderate, or weak
IFN-α/β-inducible gene signatures (based on the top 25
overexpressed IFN-α/β-inducible genes in WB of individual
SLE patients as measured by the Aﬀymetrix whole genome12 Human Genomics and Proteomics
4.03 0
1 2 5 927
1
0
0
%
n
e
u
t
r
a
l
i
z
a
t
i
o
n
N
o
n
e
u
t
r
a
l
i
z
a
t
i
o
n
S
L
E
p
a
t
i
e
n
t
s
e
r
u
m
S
L
E
p
a
t
i
e
n
t
s
e
r
u
m
+
r
e
f
e
r
e
n
c
e
a
n
t
i
b
o
d
y
S
L
E
p
a
t
i
e
n
t
s
e
r
u
m
+
1
0
μ
g
/
m
l
a
n
t
i
-
I
F
N
-
γ
m
A
b
S
L
E
p
a
t
i
e
n
t
s
e
r
u
m
+
0
.
1
μ
g
/
m
l
a
n
t
i
-
I
F
N
-
α
m
A
b
S
L
E
p
a
t
i
e
n
t
s
e
r
u
m
+
1
μ
g
/
m
l
a
n
t
i
-
I
F
N
-
α
m
A
b
S
L
E
p
a
t
i
e
n
t
s
e
r
u
m
+
1
0
μ
g
/
m
l
a
n
t
i
-
I
F
N
-
α
m
A
b
S
L
E
p
a
t
i
e
n
t
s
e
r
u
m
+
1
0
μ
g
/
m
l
a
n
t
i
-
I
F
N
A
R
m
A
b
Figure 6: Representative heat map demonstrating anti-IFN-α, -IFNAR, and -IFN-γ mAb eﬀects on healthy donor PBMC stimulated with
serumfrom1SLEpatient.Lane1:SLEpatientserumonly;Lane2:SLEpatientserumplusreferenceantibody;Lane3:SLEpatientserumplus
10μg/mL anti-IFN-γ mAb; Lanes 4–6: SLE patient serum plus increasing concentrations of anti-IFN-α mAb (0.1, 1, and 10μg/mL); Lane
7: SLE patient serum plus 10μg/mL anti-IFNAR mAb. Color represents relative neutralization (inhibition) of overexpression of individual
genes upregulated by soluble mediators in the serum of an SLE patient. The red color represents no neutralization, and green represents
neutralization of overexpression of individual genes. IFN = interferon; IFNAR = interferon associated receptor; PBMC = peripheral blood
mononuclear cells; SLE = systemic lupus erythematosus.
array) for a lower density, but high-throughput platform
(TaqMan-based assay). A scaling method was needed to
convert the IFN-α/β-inducible gene signature score based on
the top 25 most overexpressed IFN-α/β-inducible genes of
each SLE patient on the Aﬀymetrix platform to the IFN-α/β-
inducible gene signature score based on 21 genes selected for
all SLE patients for the TaqMan-based assay. This method
was implemented to compensate for 3 primary diﬀerences
between the 2 platforms: (1) the number of transcripts used
for the IFN-α/β-inducible gene signature (25 genes dynami-
cally determined for each patient on the Aﬀymetrix platform
versus a static 21-gene list on the TaqMan-based assay), (2)
the diﬀerences in sensitivity between the 2 platforms, and
(3) the scales of the dynamic ranges within each platform.
First, fold-change values were calculated (on a log2 scale)
for the 807 IFN-α/β-inducible transcripts between 35 SLE
patients (randomly selected from the 41 SLE patients whose
microarray results were conﬁrmed by TaqMan QRT-PCR;
TaqMan QRT-PCR was also used to conﬁrm microarray
results for 35 SLE patients chosen from the 54 SLE patients
in the prospective study), and the average of a set of normal
healthy controls. The top 25 most upregulated genes based
on fold-change values were determined for each patient on
theAﬀymetrixplatform(thisgenesetisallowedtovaryfrom
patient to patient depending on which IFN-α/β-inducible
genes are most overexpressed). Next, the median fold changeHuman Genomics and Proteomics 13
Table 4: Fold changes (fc; log2 transformed) and q values (calculated using FDR) for the 21 candidate PD markers in WB of 95 SLE patients
analyzed inthestudy.Dataweregenerated from95SLEpatientsfromboththeinitialstudyandtheprospectivestudyand24healthycontrols
using SAM and FDR in R (see Section 2 ). FDR = false discovery rate; SLE = systemic lupus erythematosus; SAM = signiﬁcance analysis of
microarrays; WB = whole blood.
Probe ID Gene title Gene symbol log2 fc q value (FDR) Transcript prevalence
202411 at Interferon, alpha-inducible protein 27 IFI27 3.77 2.11E-08 65.26
204415 at Interferon, alpha-inducible protein 6 IFI6 3.11 3.22E-13 76.84
213797 at Radical S-adenosyl methionine domain containing 2 RSAD2 2.82 8.04E-08 67.37
214059 at Interferon-induced protein 44 IFI44 2.81 3.96E-09 66.32
204439 at Interferon-induced protein 44-like IFI44L 2.60 2.80E-08 65.26
219211 at Ubiquitin speciﬁc peptidase 18 USP18 2.20 2.54E-09 51.58
202145 at Lymphocyte antigen 6 complex, locus E LY6E 2.17 3.39E-12 58.95
202869 at 2 ,5 -oligoadenylate synthetase 1, 40/46kDa OAS1 1.98 1.56E-08 62.11
44673 at Sialic acid binding Ig-like lectin 1, sialoadhesin SIGLEC1 1.91 2.95E-11 51.58
205483 s at ISG15 ubiquitin-like modiﬁer ISG15 1.91 3.74E-10 60.00
203153 at Interferon-induced protein with tetratricopeptide repeats 1 IFIT1 1.84 2.87E-05 64.21
218400 at 2 -5 -oligoadenylate synthetase 3, 100kDa OAS3 1.80 2.83E-07 60.00
219863 at Hect domain and RLD 5 HERC5 1.70 9.28E-08 63.16
202086 at Myxovirus (inﬂuenza virus) resistance 1 MX1 1.70 8.22E-07 63.16
205569 at Lysosomal-associated membrane protein 3 LAMP3 1.67 1.18E-09 56.84
227609 at Epithelial stromal interaction 1 (breast) EPSTI1 1.65 3.90E-07 60.00
204747 at Interferon-induced protein with tetratricopeptide repeats 3 IFIT3 1.60 7.06E-08 61.05
204972 at 2 -5 -oligoadenylate synthetase 2, 69/71kDa OAS2 1.57 1.65E-10 54.74
219684 at Receptor (chemosensory) transporter protein 4 RTP4 1.44 3.03E-06 52.63
241916 at Phospholipid scramblase 1 PLSCR1 1.23 0.00014728 55.79
241812 at DNA polymerase-transactivated protein 6 DNAPTP6 1.16 3.73E-08 42.11
was calculated from the top 25 genes for each SLE patient.
The same calculation was conducted across identical patients
using the static 21 gene set on the TaqMan-based assay.
This gene set was identical for each patient, and the median
fold change was calculated. A simple regression model was
then computed using these 2 vectors of equal length (35
median fold-change values), and the coeﬃcients from the
model were used to determine the conversion factor (from
the Aﬀymetrix platform to the TaqMan-based assay; r =
0.85) for the response threshold values to partition the SLE
patients into an IFN-α/β-inducible gene signature of high
(>10 on Aﬀymetrix; >5.53 on TaqMan), moderate (between
4a n d1 0o nA ﬀymetrix; between 1.91 and 5.53 on TaqMan),
or weak (<4o nA ﬀymetrix; <1.91 on TaqMan). Using
these scaled threshold values, the categorized signature levels
(high, moderate, or weak) that were determined using the
21 genes from the TaqMan-based assay were comparable to
those that were determined based on the top 25 upregulated
IFN-α/β-inducible genes (although it should be noted that
the threshold values between the 2 platforms are presented
on diﬀerent scales).
Figure 8 shows the stratiﬁcation of 35 SLE patients in
the initial study into groups of expressing high, moderate,
and weak IFN-α/β-inducible gene signatures in WB based
on the distribution of fold-change values (log2 scale) of
all 21 IFN-α/β-inducible genes. The median fold change of
the 21 genes for each patient (as measured by the dynamic
array from Fluidigm) was used to partition each patient
into these 3 groups. The vertical dashed lines partitioned
the 3 classes of IFN-α/β-inducible gene signature scores: 7
patients with a weak IFN-α/β-inducible gene signature =
median fold change < 1.91 (0.93 on log2 scale), 8 patients
with a moderate IFN-α/β-inducible gene signature = median
fold change between 1.91 and 5.53, and 20 patients with
as t r o n gI F N - α/β-inducible gene signature = median fold
change > 5.53 (2.47 on log2 scale). In a PCA plot for
all SLE patients proﬁled in this study (n = 95) and
for the 24 healthy control samples using the 21 IFN-α/β-
inducible genes, a clear distinction between SLE patients
with an overexpressed IFN-α/β-inducible gene signature
and those with weak or nondetectable IFN-α/β-inducible
genesignatureswasobserved(Figure 3(c)).Furthermore,the
SLE patients with weak or nondetectable IFN-α/β-inducible
gene signatures were found to cluster with healthy donors.
Importantly, the partitioning between these groups using
the 21-gene panel of IFN-α/β-inducible genes was similar to
that observed using the larger 110-gene set (Figures 3(a) and
3(b)).
We also assessed the diﬀerence in variability between the
24 normal healthy controls and the SLE patients for the 21
IFN-α/β-inducible genes selected; we conducted a variance
assessment using the three categorized IFN-α/β-inducible14 Human Genomics and Proteomics
807 IFN-α/β- inducible
probes in WB
110 IFN-α/β- inducible
probes over-expressed
in WB of SLE
807 IFN-α/β- inducible
probes in WB
807
21 33 84
56
21 of 77 probes that
map to unique genes
161 probes induced
by SLE patient sera
and neutralized by an
anti-IFN-α mAb
Figure 7: Venn diagram illustrating the three primary analyses
used in the selection process of 21 candidate PD markers for anti-
IFN-α mAb therapy in SLE: (1) 807 IFN-α/β-inducible transcripts
determined from ex vivo stimulation of healthy donor WB with
10 IFN-α subtypes and IFN-β (cyan region); (2) 110 transcripts
found to be both overexpressed in WB of SLE patients and IFN-
α/β-inducible in WB of healthy donors (combination of blue,
yellow, and red regions); (3) 161 transcripts identiﬁed by ex vivo
stimulation to be induced by SLE patient sera and subsequently
neutralized by an anti-IFN-α mAb (combination of green, yellow,
and red regions). The intersection of these three analyses provided
a list of 77 transcripts, which were ranked by magnitude and
prevalence across SLE patients (i.e., percentage of SLE patients with
a fold change of at least 2) and the top 21 unique genes were chosen.
IFN = interferon; SLE = systemic lupus erythematosus.
gene signature levels. We compared the variance of each
gene between the normal healthy controls and two groups
of SLE patients: SLE patients with a weak IFN-α/β-inducible
gene signature score (values < 4) and all SLE patients. The
reasoning for comparing the normal healthy controls to
those SLE patients with a weak IFN-α/β-inducible gene
signature score was to evaluate the normal control variability
against a set of patients that have comparable magnitude of
IFN-α/β-induciblegenesignaturescore.Wewouldexpectthe
variance for each of the 21 genes within the normal controls
and the SLE patients with a weak IFN-α/β-inducible gene
signature score to be similar.
We used an F-test to assess diﬀerences in variance for
eachofthe21genesindividuallybetweenthe2groups.Using
a Bonferroni-adjusted threshold of P<. 002 (0.05/21), a
total of 2/21 genes with signiﬁcant diﬀerences in variance
between normal healthy controls and SLE patients with a
weak IFN-α/β-inducible gene signature score were observed,
and 6/21 genes with a signiﬁcant diﬀerence in variance
between normal healthy controls and all SLE patients were
identiﬁed. All genes with signiﬁcant diﬀerences in variance
had a lower variance in the normal healthy control group.
This analysis suggests that the variability is lower among the
24 normal healthy control samples when compared to the
SLE patient samples for these 21 genes.
4. Discussion
The identiﬁcation of biomarkers that can assist in the
execution and interpretation of clinical trials may involve the
detection of unique molecular signatures that correlate with
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Figure 8: Stratiﬁcation of 35 SLE patients into groups expressing
low ((a) green), moderate ((b) gray), and high ((c) red) IFN-α/β-
inducible gene signaturebased onmedian fold change across the 21-
gene panel of IFN-α/β-inducible genes. Kernel density estimates
(i.e., histograms or frequency plots) for each SLE individual are
calculatedandgraphedusingthefoldchangeforeachofthe21genes
from each SLE patient on the log2 scale to provide a representation
ofthedistributionof21genefoldchangevalues.Theverticaldashed
lines partition the 3 classes of IFN-α/β-inducible gene signature
scores: 7 individuals with a weak IFN-α/β-inducible gene signature
= median fold change <1.91 (0.93 on log2 scale); 8 individuals with
amod e rat eIFN-α/β-induciblegenesignature =medianfoldchange
between 1.91 and 5.53; and 20 individuals with a strong IFN-α/β-
inducible gene signature = median fold change >5.53 (2.47 on log2
scale). IFN = interferon; SLE = systemic lupus erythematosus.Human Genomics and Proteomics 15
biological events [26]. In developing drugs against cytokines
and chemokines where it is diﬃcult to measure the protein
in the serum of patients, it is necessary to use biomolecules
(proteins and transcripts) that are directly downstream of
the drug targets to measure the pharmacologic eﬀect of these
drugs when they can be accurately measured. In this study,
wehaveuseda3-tieredapproachtoidentifypotentialPDand
diagnostic markers for clinical trials investigating anti-IFN-α
mAb treatments in SLE.The ﬁrst tier involved characterizing
the biological variation (patient-to-patient variation) among
SLE patients by identifying genomic biomarkers with whole
genome microarray analyses from a training panel of SLE
patients and then conﬁrming the validity of those markers in
a separate, prospective panel of SLE patients. Because of the
expensive nature of microarray analyses, the development
of an assay that could be performed on a high-throughput
platform was of utmost importance, so it could be used
in later phases of clinical trials in which several thousand
samples may be routinely assayed. Therefore, the second tier
involved validating the ﬁndings from microarray analyses in
which TaqMan-based assays were performed and optimized
for use in a premier high-throughput platform (BioMark
48.48 dynamic array from Fluidigm). In all the assays per-
formed to date, the platform provided sensitive and robust
results, with intra-array variations of ≤2% and interarray
variations of ≤5%. To further enhance the speciﬁcity of the
assay, the third tier of our approach involved the narrowing
of the number of genes to be analyzed from 807 to 77 and,
ﬁ n a l l y ,t o2 1I F N - α/β-inducible genes that were consistently
a n dm a r k e d l yo v e r e x p r e s s e di nW Bo fS L Ep a t i e n t s .T h i s
reduction in the number of genes in the screening process
allowed for the simpliﬁcation of the analysis of the results
and the increase of throughput. The robust and prevalent
overexpression of these 21 IFN-α/β-inducible genes in SLE
patients, coupled with the fact that these genes are directly
downstream of type I IFN, suggest that they may be well
suited as PD markers in clinical trials targeting IFN-α.
Additionally, the ability to use these genes to diﬀerentiate
between SLE patients with moderate-to-high overexpression
of IFN-α/β-inducible gene signature from those with weak
or nondetectable signature and healthy normal controls
suggests the use of these genes as possible diagnostic markers
in clinical trials. This may be especially true if the clinical
beneﬁts of anti-IFN-α mAb therapy occur primarily in SLE
patients who signiﬁcantly overexpress the IFN-α/β-inducible
genes in WB (Figure 3(c)). This hypothesis needs to be
validated in the clinical trials. To capture the magnitude of
IFN-α/β eﬀects in WB of SLE patients, we developed an
algorithm to calculate the IFN-α/β-inducible gene signature
scores using either a static 21 gene or a dynamic top 25 gene
list in WB of SLE patients. Results from these two methods
a g r e ew i t he a c ho t h e rv e r yw e l l( c o r r e l a t i o nc o e ﬃcient of
0.96),andalsoagreewiththeIFNscoresasdescribedbyFeng
et al. [23]( c o r r e l a t i o nc o e ﬃcients are 0.95 and 0.92 between
Feng’s method and a static 21 gene or a dynamic 25 gene
algorithm, resp., for calculating an IFN score).
SLE is an autoimmune disease characterized by the
involvement of many diﬀerent organ systems and by
immunologic abnormalities, such as the accumulation of
autoantibodies. Type I IFNs have been implicated in the
pathogenesis of SLE and some patients periodically demon-
strate elevated serum levels of type I IFNs. Furthermore,
clinical observations have suggested a role for type I IFNs
in the development of SLE; SLE symptoms have presented
in patients with cancer or viral infections who received
recombinant IFN-α therapy [27]. In recent years, microarray
analyses have provided evidence for the measurement of
type I IFN in SLE that the enhanced expression of a
number of IFN-α/β-inducible genes has been observed in
the peripheral blood of SLE patients [12, 13, 28]. The study
described in this paper is the largest study to date that
has evaluated the type I IFN eﬀect in the periphery of
SLE using a genomics approach. The ex vivo stimulation
of healthy donor PBMC with SLE patient serum samples
and subsequent neutralization with anti-IFN-α mAb or anti-
IFNAR mAb show that anti-IFN-α mAb has comparable
eﬀects of neutralizing the overexpression of type I IFN-
inducible genes as that of anti-IFNAR mAb. These results
s u g g e s tt h a ti ti sI F N - α, not other members of type I
IFN family in the serum of SLE patients, which is mainly
responsible for the induction of type I IFN-inducible genes
in WB of SLE patients.
SLE patients in this study were able to be classiﬁed as
expressing high, moderate, or weak IFN-α/β-inducible gene
signatures in the periphery. This approach will allow us to
obtain a more accurate readout on drug target neutralization
in early phases of clinical trials of anti-IFN-α mAb therapy
in SLE (patients with high-and-moderate overexpression of
IFN-α/β-inducible gene signatures are likely to provide a
more accurate assessment on PD) so that an optimal dosing
regimen can be identiﬁed for use in pivotal trial. Recently,
Anderson suggested a road map for the creation of a viable
diagnostic marker, which is composed of the following steps:
discovery, veriﬁcation/validation, and clinical implementa-
tion [29]. Currently, we are evaluating the utility of these
IFN-α/β-inducible genes as potential diagnostic markers to
identify SLE patients that might respond to anti-IFN-α mAb
therapy in several ongoing trials.
In summary, the ﬁndings described in this study provide
strong scientiﬁc evidence of IFN-α as a therapeutic target
in SLE. We also feel that the overexpression of IFN-α/β-
inducible genes, if rigorously quantiﬁed and validated, may
form the basis for developing PD and diagnostic markers in
diﬀerent stages of clinical trials of anti-IFN-α mAb therapy
in SLE. Overall, these analyses are likely to provide valuable
information during the drug development process to assist
in understanding the disease mechanism and in the selection
of the most appropriate patient population to achieve rapid
and predictable outcomes.
Acknowledgments
TheauthorswouldliketothankRhondaCroxtonandLauren
Gallagher for editorial assistance with this manuscript,
Jonathan Zmuda and Jonathan Hirsch for providing tech-
nical assistance, Chris Heid, Martin Pieprzyk, Mike Lucero,
and John Lynch from Fluidigm Corporation for their
assistance with large-scale TaqMan QRT-PCR assays, and16 Human Genomics and Proteomics
Eric Phan, Krystal Bowers, and Denise Dawson for sample
management. All authors are employees of MedImmune,
LLC. The work described in this article was supported by
MedImmune, LLC.
References
[1] United States Food and Drug Administration, “Challenge and
opportunity on the critical path to new medical products,”
http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html
#execsummary.
[2] D. Sarker and P. Workman, “Pharmacodynamic biomark-
ers for molecular cancer therapeutics,” Advances in Cancer
Research, vol. 96, pp. 213–268, 2006.
[3] United States Food and Drug Administration, “Drug-
diagnostic co-development concept paper,” http://www.fda.
gov/Cder/genomics/pharmacoconceptfn.pdf.
[4] F. W. Frueh, “Impact of microarray data quality on genomic
data submissions to the FDA,” Nature Biotechnology, vol. 24,
no. 9, pp. 1105–1107, 2006.
[ 5 ]R .D .C a n a l e s ,Y .L u o ,J .C .W i l l e y ,e ta l . ,“ E v a l u a t i o no f
DNA microarray results with quantitative gene expression
platforms,” Nature Biotechnology, vol. 24, no. 9, pp. 1115–
1122, 2006.
[6] H. Ji and R. W. Davis, “Data quality in genomics and
microarrays,” Nature Biotechnology, vol. 24, no. 9, pp. 1112–
1113, 2006.
[7] J. Hua, K. Kirou, C. Lee, and M. K. Crow, “Functional assay of
type I interferon in systemic lupus erythematosus plasma and
association with anti-RNA binding protein autoantibodies,”
Arthritis & Rheumatism, vol. 54, no. 6, pp. 1906–1916, 2006.
[ 8 ]K .A .K i r o u ,C .L e e ,S .G e o r g e ,K .L o u c a ,M .G .E .P e t e r s o n ,
and M. K. Crow, “Activation of the interferon-α pathway
identiﬁesasubgroupofsystemiclupuserythematosuspatients
with distinct serologic features and active disease,” Arthritis &
Rheumatism, vol. 52, no. 5, pp. 1491–1503, 2005.
[9] S. Vasoo and G. R. V. Hughes, “Theory, targets and therapy in
systemic lupus erythematosus,” Lupus, vol. 14, no. 3, pp. 181–
188, 2005.
[10] J. J. Hooks, H. M. Moutsopoulos, S. A. Geis, N. I. Stahl,
J. L. Decker, and A. L. Notkins, “Immune interferon in the
circulation of patients with autoimmune disease,” The New
England Journal of Medicine, vol. 301, no. 1, pp. 5–8, 1979.
[11] V. Pascual, L. Farkas, and J. Banchereau, “Systemic lupus
erythematosus: all roads lead to type I interferons,” Current
Opinion in Immunology, vol. 18, no. 6, pp. 676–682, 2006.
[12] E. C. Baechler, F. M. Batliwalla, G. Karypis, et al., “Interferon-
inducible gene expression signature in peripheral blood cells
of patients with severe lupus,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 100,
no. 5, pp. 2610–2615, 2003.
[13] L. Bennett, A. K. Palucka, E. Arce, et al., “Interferon and
granulopoiesis signatures in systemic lupus erythematosus
blood,” Journal of Experimental Medicine, vol. 197, no. 6, pp.
711–723, 2003.
[14] G.-M.H an,S.-L.Chen,N.Shen,S.Y e,C.-D .Bao ,andY .-Y .G u,
“Analysis of gene expression proﬁles in human systemic lupus
erythematosus using oligonucleotide microarray,” Genes and
Immunity, vol. 4, no. 3, pp. 177–186, 2003.
[15] A. A. Bengtsson, G. Sturfelt, L. Truedsson, et al., “Activation
of type I interferon system in systemic lupus erythematosus
correlates with disease activity but not with antiretroviral
antibodies,” Lupus, vol. 9, no. 9, pp. 664–671, 2000.
[16] M. C. Dall’Era, P. M. Cardarelli, B. T. Preston, A. Witte, and
J. C. Davis Jr., “Type I interferon correlates with serological
and clinical manifestations of SLE,” Annals of the Rheumatic
Diseases, vol. 64, no. 12, pp. 1692–1697, 2005.
[17] P. von Wussow, D. Jakschies, K. Hartung, and H. Deicher,
“Presence of interferon and anti-interferon in patients with
systemic lupus erythematosus,” Rheumatology International,
vol. 8, no. 5, pp. 225–230, 1988.
[18] D.D.Gladman,M.B.Urowitz,J.M.Esdaile,etal.,“Guidelines
for referral and management of systemic lupus erythematosus
in adults,” Arthritis & Rheumatism, vol. 42, no. 9, pp. 1785–
1796, 1999.
[19] J. Hua, K. Kirou, C. Lee, and M. K. Crow, “Functional assay of
type I interferon in systemic lupus erythematosus plasma and
association with anti-RNA binding protein autoantibodies,”
Arthritis & Rheumatism, vol. 54, no. 6, pp. 1906–1916, 2006.
[20] S. J. Rivero, E. Diaz-Jouanen, and D. Alarcon-Segovia, “Lym-
phopenia in systemic lupus erythematosus. Clinical, diagnos-
tic, and prognostic signiﬁcance,” Arthritis & Rheumatism, vol.
21, no. 3, pp. 295–305, 1978.
[21] A. D´ ıaz-Alderete, J. C. Crispin, M. I. Vargas-Rojas, and J.
Alcocer-Varela, “IL-10 production in B cells is conﬁned to
CD154+ cells in patients with systemic lupus erythematosus,”
Journal of Autoimmunity, vol. 23, no. 4, pp. 379–383, 2004.
[22] H. Wang, J. Xu, X. Ji, et al., “The abnormal apoptosis of T cell
subsets and possible involvement of IL-10 in systemic lupus
erythematosus,” Cellular Immunology, vol. 235, no. 2, pp. 117–
121, 2005.
[23] X. Feng, H. Wu, J. M. Grossman, et al., “Association of
increased interferon-inducible gene expression with disease
activity and lupus nephritis in patients with systemic lupus
erythematosus,” Arthritis & Rheumatism,v o l .5 4 ,n o .9 ,p p .
2951–2962, 2006.
[24] S. Ye, Q. Guo, J.-P. Tang, C.-D. Yang, N. Shen, and S.-L. Chen,
“Could2 5 -oligoadenylatesynthetaseisoformsbebiomarkers
to diﬀerentiate between disease ﬂare and infection in lupus
patients? A pilot study,” Clinical Rheumatology, vol. 26, no. 2,
pp. 186–190, 2007.
[25] B. Dong, Q. Zhou, J. Zhao, et al., “Phospholipid scramblase
1 potentiates the antiviral activity of interferon,” Journal of
Virology, vol. 78, no. 17, pp. 8983–8993, 2004.
[26] R. Frank and R. Hargreaves, “Clinical biomarkers in drug
discovery and development,” Nature Reviews Drug Discovery,
vol. 2, no. 7, pp. 566–580, 2003.
[27] T. A. Stewart, “Neutralizing interferon alpha as a therapeutic
approach to autoimmune diseases,” Cytokine & Growth Factor
Reviews, vol. 14, no. 2, pp. 139–154, 2003.
[ 2 8 ]M .K .C r o w ,K .A .K i r o u ,a n dJ .W o h l g e m u t h ,“ M i c r o a r r a y
analysis of interferon-regulated genes in SLE,” Autoimmunity,
vol. 36, no. 8, pp. 481–490, 2003.
[29] N. L. Anderson, “The roles of multiple proteomic platforms
in a pipeline for new diagnostics,” Molecular and Cellular
Proteomics, vol. 4, no. 10, pp. 1441–1444, 2005.